William Blair Upgrades ResMed (RMD) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
ResMed (RMD) PT Lifted to $57 on Solid Q1
October 24, 2014 11:23 AM EDTPiper Jaffray analyst David Clair reiterated an Overweight rating and boosted his price target on ResMed (NYSE: RMD) price target of $57.00 (from $55.00) following solid Q1 results.
Clair commented, "ResMed reported 1Q15 revenue of $380.4M, above consensus' $374.8M and our $373.3M... More
ResMed (RMD) Reports In-Line Q1 EPS
October 23, 2014 4:20 PM EDTResMed (NYSE: RMD) reported Q1 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $380.4 million versus the consensus estimate of $375 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More